Ticker Details
iBio, Inc. iBio Inc is a biotechnology company. It is engaged in commercializing its proprietary platform technologies, iBioLaunch for vaccines and therapeutic proteins & iBioModulator for vaccine enhancement and developing select product candidates.
IPO Date:	January 4, 2011
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$91.41M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.08 | 5.69%
Avg Daily Range (30 D):	$0.07 | 4.24%
Avg Daily Range (90 D):	$0.09 | 4.26%

Institutional Daily Volume
Avg Daily Volume:	1.64M
Avg Daily Volume (30 D):	.91M
Avg Daily Volume (90 D):	1.04M

Trade Size
Avg Trade Size (Sh.):	296
Avg Trade Size (Sh.) (30 D):	238
Avg Trade Size (Sh.) (90 D):	213

Institutional Trades
Total Institutional Trades:	137
Avg Institutional Trade:	$1.39M
Avg Institutional Trade (30 D):	$.83M
Avg Institutional Trade (90 D):	$.76M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.61M
Avg Closing Trade (30 D):	$.65M
Avg Closing Trade (90 D):	$.65M
Avg Closing Volume:	26.37K

News

Jan 9, 2026 @ 12:00 PM iBio Announces $26 Million Private Placement Source: Ibio, Inc.

Oct 23, 2025 @ 11:00 AM iBio to Participate in the Guggenheim 2nd Annual H... Source: Ibio, Inc.

Jun 24, 2025 @ 11:00 AM iBio and AstralBio Unveil Obesity Program with Nov... Source: N/A

Jan 2, 2025 @ 12:00 PM iBio Expands Cardiometabolic and Obesity Program w... Source: N/A

Oct 14, 2024 @ 2:58 PM Biopharmaceuticals Contract Manufacturing Industry... Source: Researchandmarkets.Com

Financials
	TTM	Q3 2026	Q2 2026
Basic EPS	$-.56	$-.06	$-.09
Diluted EPS	$-.56	$-.06	$-.09
Revenue	$.3M	$M	$M
Gross Profit
Net Income / Loss	$-27.61M	$-7.73M	$-8.99M
Operating Income / Loss	$-28.96M	$-8.37M	$-9.45M
Cost of Revenue
Net Cash Flow	$42.68M	$18.96M	$.56M
PE Ratio

Splits
Nov 29, 2023	1:20
Oct 10, 2022	1:25
Jun 11, 2018	1:10